Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05134740 | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).(pediTACTAL) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | withdrawn | Phase 1 | 0 | Haider MahdiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT04982354 | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Guenther KoehneOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06427369 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Sep 27, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT05823480 | Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06064279 | Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC(HAITEN-ICI) | withdrawn | Phase 1 / Phase 2 | 0 | VA Office of Research and DevelopmentFED | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586099 | Tislelizumab with Azacitidine in the Treatment of R/R AML | withdrawn | Phase 1 / Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05375253 | Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies | withdrawn | Phase 1 | 0 | University of NebraskaOTHER | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06372574 | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors | withdrawn | Phase 1 | 0 | Genentech, Inc.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | withdrawn | Phase 1 | 0 | University of California, San DiegoOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06252727 | Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) | withdrawn | Phase 1 | 0 | University of California, DavisOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT05898828 | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2024 | clinicaltrials |
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04955938 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | withdrawn | Phase 1 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Jul 5, 2024 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | withdrawn | Phase 1 | 0 | Stanford UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART A) | withdrawn | Phase 1 / Phase 2 | 0 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05082493 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas | withdrawn | Phase 1 | 0 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 0 | Jun 6, 2024 | clinicaltrials |
| NCT05807126 | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | May 2, 2024 | clinicaltrials |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05895201 | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD | withdrawn | Phase 1 / Phase 2 | 0 | Indiana UniversityOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04542603 | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT05678283 | A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05894447 | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers | withdrawn | Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05367401 | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 11, 2024 | clinicaltrials |
| NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression(GLIOASTRA) | withdrawn | Phase 1 | 0 | Philogen S.p.A.INDUSTRY | 0 | Apr 8, 2024 | clinicaltrials |
| NCT06219499 | Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 | withdrawn | Phase 1 | 0 | OncoC4, Inc.INDUSTRY | 0 | Apr 3, 2024 | clinicaltrials |
| NCT06137651 | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05952687 | Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors | withdrawn | Phase 1 | 0 | St. Jude Children's Research HospitalOTHER | 0 | Mar 27, 2024 | clinicaltrials |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma(RiNG) | withdrawn | Phase 1 | 0 | University College, LondonOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Kartos Therapeutics, Inc.INDUSTRY | 0 | Mar 22, 2024 | clinicaltrials |
| NCT03098355 | Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05613348 | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma(CAR19T2) | withdrawn | Phase 1 / Phase 2 | 0 | Zhujiang HospitalOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | withdrawn | Phase 1 | 0 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05720988 | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 22, 2024source: clinicaltrials